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Background: Although early monitoring of BK virus infection in renal transplant
patients has led to improved outcomes over the past decade, it remains unclear
whether monitoring for viremia is the best screening tool for BK virus nephropathy
(BKVN).
Methods: We conducted a retrospective review of the medical records of 368 renal
transplant recipients who had a minimum of 18 months of posttransplantation
follow-up. The relationship between the presence of BK viruria and a composite end
point of BK viremia/BKVN was established, and the predictive value of high-grade
BK viruria for development of viremia/BKVN was determined.
Results: High grade of BK viruria was present in 110 (30.1%) of the renal transplant
recipients. BK viremia/BKVN was present in 64 (17.4%) patients and was 50 times
more likely to be present in patients with high-grade BK viruria. The risk of
developing BK viremia/BKVN was 3 times higher in high-grade viruria patients, and
viruria preceded viremia by nearly 7 weeks.
Conclusion: The presence of high-grade viruria is an early marker for developing
BK viremia/BKVN. Detection of high-grade viruria should prompt early allograft
biopsy and/or preemptive reduction in immunosuppression.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Along with cytomegalovirus, polyoma BK virus (BKV) re-
mains a common cause of posttransplantation viral infections
in renal transplant recipients. Although the ﬁrst report of the
virus was in 1971 [1], its prevalence in renal transplant re-
cipients was not appreciated until the 1990s whenmore potentgy & Hypertension, Uni-
1 West Markham Street,
hon).
ty of Nephrology. Published b
/4.0/).immunosuppressive agents were used for immunosuppression.
Polyoma BKV is a small and nonenveloped DNA virus; the virus
is ubiquitous, and as much as 80e90% of the general population
is seropositive [2]. In immune-competent individuals, BKV
reactivation and viruria occur in 15e40% of the general popu-
lation [3e5], about 5e15% of renal transplant recipients
become viremic, and 20e40% become BK viruric. It causes ne-
phropathy in 1e10% of renal transplant recipients with most
cases occurring during the ﬁrst year [6e9].
An early identiﬁcation of renal transplant recipients at risk
of BK virus nephropathy (BKVN) and an early diagnosis
ensure appropriate evaluation and initiation of treatment.y Elsevier. This is an open access article under the CC BY-NC-ND license
Primer Probe base sequence
5BKfor ACAgCAAAgCAggCAAgg
BK rev GgAgTCCTggTggAgTTCC
5JCfor CTgAggAATgCATgCAgATCTA
JC rev ggAATCCTggTggAATACA
Anchor TTTTgCCATgAAgAAATgTTTgCCAgTAgATgA-FL
BKV LC 640-AAgCAACAgCAgATTCTCAACACTCAACA-PH
JCV LC 705-AAAACACAggATCCCAACACTCTACCCC-PH
IPC F ATgCCACgTAAgCgAAACA
IPC R gCATAAACgAAgCAgTCgAgT
IPC SS CACTTCCCgAATAAC-FL
IPC 705 LC 705-CggATATTTTTgATCTgACCgAAgCg-PH
BKV, BK virus; IPC, internal positive control; JCV, JC virus.
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omavirus and the lack of consensus on effective antiviral
therapy remain [10e12]. Although Babel et al [13] showed in
2009 that sustained BK viruria was a reliable marker for
development of BKV-associated nephropathy, checking for
viruria using quantitative polymerase chain reaction (PCR) has
not been widely adopted. Current guidelines recommend
monitoring for viremia [14,15].
As it is known that viruria precedes viremia in all renal
transplant patients who eventually develop BKVN, our inves-
tigation was to see if the detection of high-grade viruria is a
good screening test.
Methods
Study design
We retrospectively reviewed the medical charts of all renal
transplant patients who were transplanted at the University of
Chicago Medical Center (UCMC) between December 2001 and
August 2009. This study was approved by the Institutional
Review Board of the University of Chicago. Data regarding the
transplant recipient demographics and HLA type, donor de-
mographics and HLA type, urine and whole-blood/plasma BK
PCR values, and results of transplant renal biopsies were
collected. We deﬁned BK viremia as >2,000 copies/mL in the
blood sample.
Inclusion criteria
All patients who received a renal transplant at the UCMC
were followed up at the UCMC for at least 18 months after
transplantation and also had at least 1 urine specimen exam-
ined for the presence of BKV by quantitative PCR.
Exclusion criteria
We excluded renal transplant patients who suffered the loss
of allograft immediately after transplantation because of graft
thrombosis or other complications, were lost to follow-up,
moved to a different place immediately after transplantation,
died in the early posttransplantation period, or had no urine
test done for BKV monitoring.
BKV monitoring
All renal transplant recipients have their urine samples
checked for BKV by PCR at least once a month for the ﬁrst
6months and then every 2e3months for additional 6months. If
a high-grade viruria (i.e., viral load greater than the upper limit
of the detectable range) [9,16] is detected, a secondurine sample
is obtained in 2 weeks. If 2 consecutive urine samples show
high-grade viruria, whole-blood/plasma BK PCR is ordered.
BKV PCR
The BKV quantitative PCR assay at the UCMC is a multiplex
assay that detects both BK and JC virus (JCV) DNA. It was initially
validated for whole blood (EDTA) and urine specimens, as well as
for cerebrospinal ﬂuid (qualitative JCV results only). DNA extrac-
tion is performed using the MagNA Pure LightCycler (LC) (Roche
Diagnostics, Indianapolis, IN, USA). An initial volume of 200 mL ofpatient sample is extracted and concentrated in 50 mL of eluate,
using the MagNA Pure LC Total Nucleic Acid Isolation Kit. Two
different known concentrations of positive samples containing
BKV target, aswell as a negative control containing bacterial DNA,
are processed in each sample run to verify the accuracy of
extraction.
Beginning December 14, 2009, processing was changed to
plasma instead of whole blood. In addition, extraction was
performed on an initial volume of 200 mL of patient sample and
concentrated in 100 mL of eluate, using the MagNA Pure LC DNA
Isolation Kit I. These changes improved the reliability of
detection of low concentrations of BKV from blood specimens.
The assay is speciﬁcally adapted for PCR in glass capillaries
using the LC Instrument from Roche Diagnostics. A 219-base
pair (bp) fragment of the BKV and a 174-bp fragment of the JCV
genome are ampliﬁed with speciﬁc primers and detected with
probes labeled with LightCycler Red 705 (JCV) or with Light-
Cycler Red 640 (BKV). An additional PCR product of 278 bp is
formed from the internal positive control DNA to verify the
absence of ampliﬁcation inhibitors in negative samples.
Primers and probes were purchased from TIB MOLBIOL (Berlin,
Germany):The target is the gene for large T antigen. Master mix is
prepared using LC FastStartPLUS DNA Master Hybridization
Probes from Roche Diagnostics. The reaction mix is 5 mL of
patient eluate added to 15 mL of master mix. The protocol in-
cludes 45 cycles of PCR.
Up to 6 dilutions of a stock solution of cloned target DNA are
processed in each run and used to generate a standard curve to
determine the absolute quantiﬁcation of DNA present in posi-
tive patient samples. Quantiﬁcation was reported in a range
from 2,500 to 25 million copies/mL of patient sample; positives
outside the range are reported as greater than (>) or less than
(<). Beginning on December 14, 2009, the upper limit of the
reportable range was extended to 50 million copies/mL of pa-
tient sample. The detection limit for the assay was validated as
equivalent to 500 copies/mL of patient sample (10 copies per
reaction). For positive samples, melting curve analysis is per-
formed to verify the identiﬁcation of the ampliﬁed product.Renal allograft biopsy
An increase in the serum creatinine level of 0.4 mg/dL or
higher without a probable cause led to an ultrasound-guided
renal allograft biopsy. An 18-gauge spring-loaded biopsy gun
was used to obtain 2e3 cores, and the samples were prepared
and reviewed under light microscopy and immunoﬂuores-
cence. BKVN was deﬁned by the presence of typical viral
Table 1. Baseline characteristics of patients receiving renal
transplant between January 1, 2004 and December 31, 2009 (N¼ 368)
Patient characteristics No. of patients or
mean ± SD
Donor type
Deceased-donor renal transplant 230 (62.5)
Living-donor kidney (related or unrelated) 109 (29.6)
Multiorgan 29 (7.9)
Donor age (y) 39.3 ± 14.7
(range, 0.5e16)
Primary kidney disease
Diabetes mellitus 114 (31.0)
Hypertension 61 (16.6)
Unknown 48 (13.0)
FSGS 23 (6.3)
PKD 21 (5.7)
Congenital kidney diseases 15 (4.1)
SLE and other CT disorders 15 (4.1)
IgA nephropathy 13 (3.5)
Other GNs (PSGN, MGN, etc) 20 (5.4)
Miscellaneous 38 (10.3)
Recipient gender
Female 133 (36.1)
Male 235 (63.9)
Recipient age at transplant (y) 47.7 ± 14.4
(range, 0.9e79)
Recipient race
Caucasians 121 (32.9)
African Americans 165 (44.8)
Hispanic 33 (9.0)
Asian 9 (2.4)
Unknown 40 (10.9)
HLA mismatches 4.2 ± 1.7
Induction
Antiethymocyte globulin 233 (63.3)
IL-2 receptor antagonist 123 (33.4)
Other/unknown 12 (3.3)
Maintenance immunosuppression
FK/MMF or MPS/pred 343 (93.2)
CsA/MMF or MPS/pred 7 (1.9)
Bela/MMF/pred 5 (1.4)
CsA or FK/sirolimus/pred 6 (1.6)
Other 7 (1.9)
Data are presented as n (%) or mean ± SD.
CsA, cyclosporine; CT, connective tissue; FK, tacrolimus; FSGS, focal
segmental glomerulosclerosis; GN, glomerulonephritis; HLA, human
leukocyte antigen; IgA, immunoglobulin A; IL-2, interleukin 2; MGN,
membranous; MMF, mycophenolate mofetil; MPS, mycophenolate so-
dium; PKD, polycystic kidney disease; PSGN, post-streptococcal
glomerulonephritis; SLE, systemic lupus erythematosus.
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periodic acideSchiff methods and positive polyomavirus SV40
large T antigen (Tag) expression in tubular epithelial nuclei by
standard immunohistochemistry (Ab-2; Oncogene Research
Products, Cambridge, MA, USA).
Statistical analysis
The primary objective of this study was to determine the
relationship between the presence of BKV replication in the
urine (viruria) and concurrent or subsequent BK viremia or
nephropathy. The composite event of interest, BKþ, was
deﬁned as either positive whole-blood or plasma BKV DNA by
quantitative PCR, or a positive biopsy test for BKVN. BKþ date
was deﬁned as the date when BKV was ﬁrst detected in the
blood or biopsy. For patients who had no evidence of BKV in
any of the blood or biopsy tests (or BKe), the reference test date
was deﬁned as that of the last blood test or biopsy date.
A positive urine test (viruria) was deﬁned as urine BK PCR
count of  25 million copies/mL. Urinary BK PCR counts were
further classiﬁed as none (0), low (< 25 million copies/mL), or
high ( 25 million copies/mL).
We ﬁrst examined the association between the reference
BKþ test and the presence of BKV in the patients' urine test
closest to it in time (within 30 days). A chi-square test was used
to test for association between BKþ and viruria, and an Armit-
age trend test was used to determine whether the proportion of
BKþ increased across the none/low/high viruria groups.
The association between viruria and BKþ status was also
examined among all same-day urine and blood/biopsy tests. We
used a generalized linear mixed model where BKþ was the
outcome variable, urine BK count was the predictor, and patient
random effect was included to account for serial tests within the
patient. A receiver operating characteristic (ROC) curve was
constructed based on the ﬁtted generalized linear mixedmodel,
and the area under the ROC curve (AUC) was calculated [17].
To assess whether a positive urine test increases the risk of
developing BKþ in the future, we used the Cox proportional
hazards model with time-varying covariate (urine positivity).
Time to ﬁrst BKþ was deﬁned as the time from the date of
transplantation to the ﬁrst positive blood or biopsy test. Pa-
tients without a positive test were censored at the date of their
last available blood/biopsy date as described previously. The
KaplaneMeier method was used to estimate the survival curve.
Results
We identiﬁed 368 patients who underwent renal trans-
plantation at the UCMC between December 2001 and August
2009 and met the inclusion criteria of our study. The baseline
characteristics of these patients are shown in Table 1. The
average age of recipientswas 47.8 years (range, 0.9e79), and 133
(36%)were female. The average age of the donorswas 39.3 years
(range, 0.5e76). Two hundred thirty (62.5%) of 368 patients
received adeceased-donorkidney,whereas 109 (29.6%) patients
received a living-donor transplant. Of the 230 deceased donor
renal transplants, 13 were second renal transplants and 2 were
third renal transplants. The remaining 29 patients received
multiorgan transplants (e.g., simultaneous pancreas kidney
transplant, liverekidney, heartekidney, livereheartekidney,
or heartepancreasekidney). Primary kidney diseases included
diabetes (31.0%), hypertension (16.6%), unknown (13.0%), focalsegmental glomerulosclerosis (6.3%), polycystic kidney disease
(5.7%), systemic lupus erythematosus (4.1%), congenital kidney
disease (4.1%), and IgA nephropathy (3.5%). There was no ABO-
incompatible or desensitized renal transplantation. Two hun-
dred thirty-three (63.3%) of 368 recipients were induced with
thymoglobulin, whereas 123 (33.4%) received interleukin 2
receptor antagonists as their induction agent. Three hundred
forty-three of 368 patients (93.2%) received a maintenance
regimen consisting of tacrolimus, mycophenolate, and predni-
sone. Sixty-nine of 368 patients (18.8%) were considered at high
risk for rejection (i.e., repeat transplantation, highly sensitized
[panel-reactive antibody > 50%], multiorgan [excluding liver-
ekidney], and bilateral renal transplants; data not shown).Prevalence of BK viruria and BK viremia/BKVN
Of the 368 patients who underwent testing for BKV in their
urine, 216 (59.2%) had nonzero BKV counts. A high level of BK
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tients. At least 1 blood or biopsy BK test was available for all
patients. Blood tests for BKV DNA were available for 361 pa-
tients, and 52 (14.4%) were positive. Transplant renal biopsies
were performed in 248 patients, and 46 (18.6%) stained positive
for SV40 large T antigen. The combined incidence of BK viremia
and nephropathy was 17.4% (64 BKþ results).0.
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Figure 1. Time to ﬁrst evidence of viremia or BKVN estimated using the
method of KaplaneMeier.
BKVN, BK virus nephropathy.Relationship between BK viruria and BK viremia/BKVN
A urine test done within 30 days of the reference blood or
biopsy test was available for 318 (86.4%) patients. Of these, 274
(74.4%) patients had same-day tests, and 31 and 13 patients had
a urine testwithin 30 days before or after the reference blood or
biopsy test date, respectively. Sixty-two of the 318 patients
(19.5%) were BKþ. Median urine BK counts were 0 (range,
0e36.2 million copies/mL) among BK patients and 25 million
copies/mL (range, 0e25 million copies/mL) among BKþ pa-
tients. The proportion of BKþ patients was higher among pa-
tients with a positive urine test (77.1% vs. 5.8%, P< 0.0001).
When BK urine presence was categorized as none (0 count),
low (< 25 million), and high ( 25 million), the proportion of
BKþ patients across these groups was 1.1%, 19.7%, and 77.1%,
respectively (P < 0.0001, trend test).
Next, we considered all concurrent (same-day) urine and
blood/biopsy tests. There were 2,724 instances when both
types of tests were performed among 358 patients (the number
of test instances ranged from 1 to 34 per patient). Agreement
was high between the blood/biopsy and urine tests (88%) when
a positive urine test was deﬁned as  25 million (Table 2), and
only a small proportion of cases were positive both on blood/
biopsy and urine (5.7%). Agreement was lower when a positive
urine test was deﬁned as > 0 (62.75%). Among the urine-
negative tests, only 20 of 2,262 (0.7%) were BKþ, whereas a
substantial proportion of urine-positive tests was BK (307 of
462, 66.5%). The sensitivity and speciﬁcity of high-level BK
viruria for diagnosing BK viremia/BKVN were 88.57% and
87.96%, respectively. The positive and negative predictive
values were 33.55% and 99.12%, respectively.Predictive value of BK viruria for the presence of BK viremia/
BKVN
We further analyzed the value of the presence and degree of
BK viruria as a predictor of blood/biopsy positivity using the
ROC analysis. The generalized linear mixed-effects model was
ﬁtted with urine BK count as the predictor, and the resulting
AUC was 0.97, indicating that concurrent presence of BK in the
urine is a very strong predictor of the presence of viremia and/
BKVN. In a separate model, we found that those who had 25Table 2. Concordance between concurrent urine and blood/biopsy
tests, using different cut points for deﬁning viruria (N; percent of all
2,724 concurrent tests)
Urine viruria cut point BK BKþ Total
Urine  25 million
No 2,242 (82.3) 20 (0.7) 2,262 (83.0)
Yes 307 (11.3) 155 (5.7) 462 (17.0)
Urine > 0
No 1,537 (56.4) 3 (0.1) 1,540 (56.5)
Yes 1,012 (37.2) 172 (6.3) 1,184 (43.5)
Data are presented as n (%).million or higher BK count in the urine were nearly 50 times
more likely to also have a positive blood/biopsy result than
those who had < 25 million counts (odds ratio, 50.33; 95%
conﬁdence interval, 28.6e88.5; P < 0.0001).Predictive value of BK viruria for the development of BK
viremia/BKVN
We explored whether the presence of high levels of BKV in
the urine is associated with an increased risk of subsequent
detection of BKV in blood or biopsy. The majority of patients
(358, 97.3%) had at least 1 urine test available before the
reference blood/biopsy evaluation, and 72 (20.1%) of these
urine tests were positive ( 25 million copies/mL). Among
patients with a positive urine test, 24 (33.33%) subsequently
developed BKþ, whereas only 33 of 286 (11.5%) patients with
all negative urine tests subsequently developed BKþ.Figure 2. ROC curve for BK viruria as a predictor of blood/biopsy pos-
itivity.
ROC, receiver operating characteristic.
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Among the 368 patients, 64 developed BK viremia or
nephropathy (or BKþ) during 18 months after transplantation.
Time to BKþ was estimated using the KaplaneMeier method,
and patients who did not develop viremia or nephropathy (i.e.,
BK) were censored at the time of the last blood/biopsy test.
BKþ rates at 6, 12, and 18 months were 12.8%, 18%, and 24.8%,
respectively (Figs. 1 and 2). Median follow-up time for patients
who did not develop viremia/BKVN was 11.9 months (range,
0.3e25.2).
Median time from the ﬁrst positive urine test until BKþ
(n ¼ 24) was 35 days (range, 12e266), and median follow-up
time for those who never developed viremia/BKVN was 198
days (range, 14e490). The median number of urine tests before
BKþ diagnosis or end of follow-up period was 5 (range, 1e25).
A time-varying covariates Cox model revealed that a positive
urine test greatly increased the hazard of subsequent devel-
opment of BKþ (hazard ratio, 7.0; P < 0.001).
Discussion
The art and science of managing renal transplant recipients
centers around the Goldilocks principle: providing immuno-
suppression that is “just right” to prevent allograft rejection
while minimizing the risk of opportunistic infections and ma-
lignancies. It requires vigilant monitoring for allograft
dysfunction and detection of signs and/or symptoms of
opportunistic infections. Screening and diagnosis of BKV
infection/BKVN in renal transplant recipients is fraught with
many obstacles:
1. Negative renal allograft biopsy does not rule out BKVN because
of the focal presence of cytopathic changes [18]dand SV40
staining may not detect all infected cells [19].
2. Quantitative DNA PCR tests are not standardized, and direct
comparison of the viral load is not possible [20,21].
3. Currently, there are no safe and effective antiviral agents avail-
able, and most data on the use of antiviral agents are based on
small nonrandomized studies [10].
4. Reduction of immunosuppression is the recommended treat-
ment, but this can lead to allograft rejection/loss.
5. Although early diagnosis of BKVN on the biopsy, with subse-
quent reduction or modiﬁcation of immunosuppression [22],
often leads to resolution of infection and prevents further
decline in the kidney allograft function in many cases, the
damage from BKVNmay not be reversed despite modiﬁcation of
immunosuppression [23,24]. A large percentage of these pa-
tients are left with chronic allograft dysfunction, which leads to
a shortened allograft survival [25].
Nevertheless, BK viremia and BKVN are almost always pre-
ceded by a period of detectable viruria [13]. Therefore, as
compared with the following BKV in the blood, monitoring of
BKV in the urine may lead to earlier detection of the viral
replication in the allograft. Therefore, in our study, we sought to
determinewhether a high-level BK viruriawas predictive of the
presence or development of BK viremia or BKVN.
In the present study, we found high prevalence of BK viruria
(59.2%) in our renal transplant patients during the ﬁrst 18
months after transplantation. Almost half of these patients had
high levels of BK viruria (> 25 million copies/mL). Theprevalence of viremia alone was 14.4% and when combined
with nephropathy was 17.4%. Our ﬁndings are in linewith those
of other investigators [13,25,26].
The analyses further showed that when a urine test was
performed within 30 days of the BK blood test or biopsy, the
median BK urine counts were signiﬁcantly higher among the
patients with viremia/BKVN as compared with those without
(25 million copies/mL vs. 0 copies/mL). Conversely, the pro-
portion of patients with positive BK blood test or biopsy was
signiﬁcantly higher in the patients with viruria (77.1% vs. 5.8%,
P < 0.0001). Furthermore, the proportion of patients with
viremia/BKVN increased as the level of viruria increased (1.1%
in no viruria, 19.7% with urine BK viral load < 25 million, and
77.1% with urine BK viral load  25 million).
When the BK testing in the urine and blood/biopsywas done
on the same day, a negative urine value (< 25 million copies/
mL) highly corresponded with a negative blood/biopsy result,
with only 0.9% of tests being positive for viremia or nephrop-
athy in the absence of high levels of viruria. The presence of
high-level viruria was found to be a very strong predictor of
concurrent systemic BK infection (AUC ¼ 0.97). Furthermore,
patients with high levels of BK viruria (> 25 million) were 50
times more likely to have concomitant viremia/BKVN than
those with low levels of BK viruria (< 25 million).
This study also shows that for patients with high levels of
viruria in the early posttransplantation period, the risk of
subsequently developing BK viremia/BKVN is 3 times higher
than those without.
We chose to check the urine PCR because of its ease of
sample collection and the high negative predictive value of the
test. In addition, monitoring for BK viruria is also potentially
beneﬁcial as Masutani et al [27] showed that patients who have
frequent viruria are more prone to acute rejection episodes.
We also recognize issues associated with urine PCR tests: (1)
a large percentage of patients with viruria may not develop
viremia or nephropathy (low positive predictive value) and (2)
the lag in viral load reduction on lowering immunosuppression.
However, early diagnosis using urine PCR may become more
useful when an effective antiviral therapy becomes available,
and a prompt intervention can result in eradication of viremia
before irreversible tissue damages are done.
We recognize the limitations of our studydretrospective and
single-center study; however, the large sample size and the long
duration of monitoring period make its ﬁndingsdthe presence
of high level of BK viruria can be used as a surrogate marker for
viremia or nephropathydmeaningful and should be followed
up either with an allograft biopsy or with a preemptive reduc-
tion or modiﬁcation of immunosuppression.
We propose that BK monitoring should be routinely per-
formed by serial examinations of urinary BK viral loads. At our
center, the cutoff for BK levels in urine that indicated high risk
was determined at  25 million copies/mL. However, the cutoff
values should be determined by each center as there are
different assays that use different probes for detection of BKV.
Persistence of high levels of viruria should not be ignored and
should be considered a risk factor for development of and
potentially a marker for the presence of BKVN.
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